Topotecan-induced bronchiolitis.
Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity. Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer. Reported dose-limiting adverse reactions to topotecan are primarily hematologic in nature. To date, only one other case of lung toxicity in a patient taking topotecan has been reported. The authors describe the development of obliterative bronchiolitis, as evidenced by radiographic and pulmonary function testing abnormalities, in a 61-year-old woman who presented with dyspnea, and who was receiving topotecan for peritoneal carcinomatosis.
Department of Internal Medicine, Madigan Army Medical Center, Tacoma, WA 98431, USA. colin.edgerton@nw.amedd.army.mil
Colin C
CC
Edgerton
Matthew
M
Gilman
Bernard J
BJ
Roth
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001988:Bronchiolitis / Q000139:chemically induced*; D002277:Carcinoma / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000009:adverse effects
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D019772:Topotecan